Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Gérard Babany"'
Autor:
Gérard Babany, Hervé Maisonneuve
Publikováno v:
La Presse Médicale. 44:586-589
La Presse Medicale - In Press.Proof corrected by the author Available online since jeudi 7 mai 2015
Autor:
Pascale Chouinard, Noelle Bendersky, Claire Francoz, François Durand, Nathalie Boyer, Blaise K. Kutala, L. Elkrief, Richard Moreau, Dominique Valla, Gérard Babany, Patrick Marcellin, Béatrice Larroque, Pierre-Emmanuel Rautou, David Hajage
Publikováno v:
Hepatology. 60:823-831
In patients with chronic hepatitis C (CHC), cirrhosis is associated with age, gender, diabetes, alcohol abuse, and coinfection with human immunodeficiency virus (HIV) or hepatitis B virus (HBV). The effect of these factors on the outcome of cirrhosis
Autor:
J. Marc Chapplain, Sandrine Bertrais, Jean-Pierre Zarski, Julien Chaigneau, M. Eddine Charaf, Paul Calès, Gérard Babany, Nathalie Sturm, Christian Michelet
Publikováno v:
Journal of Viral Hepatitis. 19:e143-e153
We evaluated whether quantitative measurements of liver fibrosis with recently developed diagnostics outperform histological staging in detecting natural or interferon-induced changes. We compared Metavir staging, morphometry (area and fractal dimens
Autor:
Gérard Babany, P. Melin, A Pinta, Michèle Chevallier, Jean-Pierre Zarski, Nathalie Sturm, Corinne Bonny, Philippe Sogni, Stéphanie Rouanet, Alice Cheveau, Hervé Desmorat, J.-J. Raabe
Publikováno v:
Liver International. 30:1049-1058
Background The efficacy of a maintenance therapy in non-responder patients with chronic hepatitis C has been essentially evaluated by histological semiquantitative scores. Aim The aim was to evaluate the efficiency of 2 years of treatment with pegint
Autor:
Gérard Lachâtre, Annick Rousseau, Gérard Babany, Pierre Marquet, François-Ludovic Sauvage, Véronique Loustaud-Ratti
Publikováno v:
Therapeutic Drug Monitoring. 32:237-241
Ribavirin pharmacokinetic and exposure effect trials based on either plasma or serum concentrations have yielded diverging results. This study aimed to compare ribavirin concentrations in serum and plasma and to investigate the influence of blood col
Autor:
Véronique Loustaud-Ratti, Marie-Claude Gagnieu, Françoise Stanke-Labesque, Pierre Marquet, Gérard Babany
Publikováno v:
Fundamental & Clinical Pharmacology. 24:401-406
Recent studies suggest the potential interest of ribavirin therapeutic drug monitoring to improve sustain virological response rate in hepatitis C virus-infected patients. The present review details the pharmacokinetic properties of ribavirin, sugges
Autor:
Françoise Stanke-Labesque, Jean-François Jourdil, Pierre Marquet, Marie-Claude Gagnieu, Gérard Babany, François-Ludovic Sauvage
Publikováno v:
Therapeutic Drug Monitoring. 31:374-381
Ribavirin, a nucleoside analog, is administered in combination with interferon to patients with chronic hepatitis C. To evaluate the feasibility of ribavirin therapeutic drug monitoring, we investigated the influence of blood collection and preanalyt
Autor:
Véronique Loustaud-Ratti, Marie-Claude Gagnieu, Christian Trepo, Marianne Maynard, Gérard Babany, Françoise Stanke-Labesque, Pierre Marquet
Publikováno v:
Gastroentérologie Clinique et Biologique. 33:580-583
Autor:
Hervé, Maisonneuve, Gérard, Babany
Publikováno v:
Presse medicale (Paris, France : 1983). 44(6 Pt 1)
Autor:
H. Desmorat, F Bloch, Jacques Izopet, Daniel Fischer, B Mesnard, Pierre-Henri Bernard, François Bailly, J.-P. Lagasse, P. Couzigou, C Sayada, P Chossegros, G Force, Xavier Causse, Jean-Louis Payen, Marie-France Saint-Marc Girardin, J.C. Barbare, D Trois Vallets, Jean-Dominique Poveda, JC Schmit, Alexandre Pariente, P Sogni, Jean-Pierre Zarski, Albert Tran, Gérard Babany, L. Bettan, A Gauthier, Y Bacq, Eveline Boucher, Puig P Laurent, JM Lang, C Douvin, R Olivares, C Housset, Nathalie Boyer, W Rozenbaum, J.-J. Raabe, C Van Lemmens, O Danne, F. Montestruc
Publikováno v:
Journal of Hepatology. 32:1003-1010
Background/Aim: The aim of this prospective study was to compare the response to alfa-interferon treatment of chronic hepatitis C in two groups of patients: coinfected with human immunodeficiency virus (HIV) (G I) or not (G II). Methods: One hundred